Showing 821-830 of 1564 results for "".
- T-Cell Immunity Persists in Rituximab-Treated RA Patients, Recasting the Role of COVID-19 Vaccineshttps://reachmd.com/news/t-cell-response-in-sars-cov-2-vaccination-persistence-in-rituximab-treated-rheumatoid-arthritis/2474224/In the ongoing effort to optimize COVID-19 protection for immunocompromised patients, new research is shifting the spotlight toward T-cell immunity. For rheumatoid arthritis patients treated with rituximab—a B-cell depleting therapy—recent findings reveal that vacc
- New Technology Reverts Colon Cancer Cells to Normal-Like State Without Traditional Side Effectshttps://reachmd.com/news/new-technology-reverts-colon-cancer-cells-to-normal-like-state-without-traditional-side-effects/2470830/A team of researchers from KAIST has unveiled a revolutionary approach to cancer treatment that reprograms colon cancer cells into a state resembling normal cells rather than destroying them. This method, led by Professor Kwang-Hyun Cho from the Department of Bio and Brain Engineering, offers a p
- Early-Life Clinical and Hematological Profiles: Distinguishing Infants and Toddlers with Sickle Cell Diseasehttps://reachmd.com/news/early-life-clinical-and-hematological-profiles-distinguishing-infants-and-toddlers-with-sickle-cell-disease/2483953/Recent research shows a substantially higher early hospital admission burden among children with sickle cell disease, driven largely by severe anemia and divergent hematologi
- Researchers Identify Key Characteristics Associated with Improved CAR T Outcomes in Large B Cell Lymphomahttps://reachmd.com/news/researchers-identify-key-characteristics-associated-with-improved-car-t-outcomes-in-large-b-cell-lymphoma/2456904/TAMPA, Fla. — Chimeric antigen receptor T-cell therapy, or CAR T, has dramatically improved the treatment of certain blood cancers. Initially approved for
- Acidosis Drives Metabolic Rewiring in Tumors, Promoting Cancer Cell Survival Under Stresshttps://reachmd.com/news/acidosis-drives-metabolic-rewiring-in-tumors-promoting-cancer-cell-survival-under-stress/2483934/A new study reveals that acidosis—a common but often overlooked feature of the tumor microenvironment—plays a central role in orchestrating how cancer cells adapt to harsh metabolic conditions.
- Strategic Insights into Heart Failure Management: The Roles of Finerenone and Vascular Cell Adhesion Moleculeshttps://reachmd.com/news/strategic-insights-into-heart-failure-management-the-roles-of-finerenone-and-vascular-cell-adhesion-molecules/2482946/Heart failure management is evolving, driven by emerging drugs like finerenone and by emerging research on novel biomarkers such as vascular cell adhesion molecules. With ongoing developments, cardiologists are reassessing treatment strategies through the dual lens of pharmacotherapy and bi
- Advancing Tuberculosis Diagnosis in Children: The Promise of Cell-Free DNA Next-Generation Sequencinghttps://reachmd.com/news/advancing-tuberculosis-diagnosis-in-children-the-promise-of-cell-free-dna-next-generation-sequencing/2471437/Childhood tuberculosis presents unique diagnostic challenges due to low bacterial loads, but innovative approaches using cell-free DNA next-generation sequencing offer promising improvements in detection and patient management. Emerging diagnost
- UMSOM Researchers Identify Safety of a Potential New Treatment to Manage Complications from Sickle Cell Diseasehttps://reachmd.com/news/umsom-researchers-identify-safety-of-a-potential-new-treatment-to-manage-complications-from-sickle-cell-disease/2462695/Newswise — A drug approved to treat pulmonary arterial hypertension may be effective at managing hypertension and end-organ damage in patients with sickle cell disease, according to a new study published in
- Three Lessons Learned in Adoptive Cell Therapy Trials: A Look at the Road Ahead for Immunologyhttps://reachmd.com/news/three-lessons-learned-in-adoptive-cell-therapy-trials-a-look-at-the-road-ahead-for-immunology/2462683/An exploration of the emerging issues for autoimmune drug developers in translating oncological adoptive cell therapy experience into autoimmune trials.By Abhi Gupta, Kendra Keogh, James Barwick-Silk and Manfred Lauth
- Subcutaneous Nivolumab as Effective as IV for Renal Cell Carcinoma, with Much Faster Treatment Time: Clinical Trialhttps://reachmd.com/news/subcutaneous-nivolumab-as-effective-as-iv-for-renal-cell-carcinoma-with-much-faster-treatment-time-clinical-trial/2456999/Subcutaneous injection of the immunotherapy nivolumab (brand name Opdivo) is noninferior to intravenous delivery and dramatically reduces treatment time in patients with renal cell carcinoma, as seen in the results of a large phase 3 clinical trial reported today at the 2024